Search results for "Molecular-Weight"

showing 10 items of 72 documents

Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients

2005

Outpatient treatment of deep vein thrombosis (DVT) has become a common practice in uncomplicated patients. Few data are still present in patients with comorbidity (such as cancer) or concomitant symptomatic pulmonary embolism. Cancer patients with DVT are often excluded from home treatment because they have a higher risk of both bleeding and recurrent DVT. We tested the feasibility and safety of the Home Treatment (HT) program for acute DVT a PE in cancer patients. Patients were treated as outpatients unless they required admission for other medical problems, were actively bleeding or had pain that requires parenteral narcotics. Outpatient treatment was with low molecular weight heparin (LM…

AdultMalemedicine.medical_specialtymedicine.drug_classHome NursingDeep veinLow molecular weight heparinSelf Administration.Patient Education as TopicRecurrenceNeoplasmsmedicineHumansAgedAged 80 and overVenous Thrombosisbusiness.industryWarfarinCancerHematologyHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisComorbidityHome Care ServicesPulmonary embolismSurgeryHospitalizationVenous thrombosismedicine.anatomical_structureOncologyFeasibility StudiesPatient ComplianceFemaleWarfarinbusinessPulmonary Embolismmedicine.drugFollow-Up Studies
researchProduct

The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study.

2005

AbstractIn contrast with extensive documentation in patients treated with unfractionated heparin (UFH), the incidence of heparin-induced thrombocytopenia (HIT) in medical patients receiving low-molecular-weight heparin (LMWH) is less well defined. In a prospective cohort study, the platelet count was monitored in 1754 consecutive patients referred to 17 medical centers and treated with LMWH for prophylaxis or treatment of thromboembolic disorders. The diagnosis of HIT was accepted in case of a platelet drop of at least 50%, the absence of obvious explanations for thrombocytopenia, and the demonstration of heparin-dependent IgG antibodies. HIT developed in 14 patients (0.80%; 95% CI, 0.43%-1…

AdultMalemedicine.medical_specialtymedicine.drug_classImmunologyLow molecular weight heparinheparinPlatelet Factor 4BiochemistryCohort StudiesRisk FactorsHeparin-induced thrombocytopeniaInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)IncidenceCell BiologyHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaSurgeryClinical trialTreatment OutcomeFemaleComplicationbusinessCohort studymedicine.drugBlood
researchProduct

Laboratory control of minimal heparinization during haemodialysis in patients with a risk of haemorrhage

1994

Abstract For patients undergoing dialysis with a high risk of haemorrhage there is no standardized procedure for anticoagulation during extracorporeal circulation. Minimal heparinization with a dose equivalent to half that used for chronic haemodialysis was employed in 49 patients (125 haemodialyses) performed after operative interventions (83.3%), after haemorrhagic events (5.2%) and after invasive investigations (11.5%). Using a biocompatible membrane and a low molecular weight heparin (bolus dose 500-1300 U; continuous infusion 100-400 U) it was possible to complete haemodialysis in 74 cases (Group 0) without clots appearing in the venous bubble trap of the tubing system. In 30 cases (Gr…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAntithrombin IIILow molecular weight heparinHemorrhageFibrin Fibrinogen Degradation ProductsClinical ProtocolsRenal DialysisRisk FactorsmedicineHumansIn patientRisk factorDialysisAgedMonitoring PhysiologicDose-Response Relationship Drugbusiness.industryAnticoagulantExtracorporeal circulationHematologyGeneral MedicineHeparinHeparin Low-Molecular-WeightMiddle AgedAntifibrinolytic AgentsSurgeryFemaleHemodialysisbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss…

2003

Objective To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL). Methods We examined 40 women with recurrent abortion (at least 3 occurrences) and repeatedly positive test results for anticardiolipin or lupus anticoagulant. The subjects were randomly assigned to treatment with IVIG or LMW heparin plus low-dose aspirin. Both therapies were started when the women were pregnant as documented by a positive urine test. IVIG was stopped at the thirty-first week of gestation, aspirin at the th…

Adultmedicine.medical_specialtyAbortion HabitualAdolescentmedicine.drug_classImmunologyLow molecular weight heparinGastroenterologyRoute of administrationRandom AllocationRheumatologyAntiphospholipid syndromePregnancyInternal medicinemedicineImmunology and AllergyHumansPharmacology (medical)PregnancyLupus anticoagulantAspirinAspirinbusiness.industryAnticoagulantPregnancy OutcomeAnticoagulantsImmunoglobulins IntravenousHeparinHeparin Low-Molecular-Weightmedicine.diseaseAntiphospholipid SyndromeSurgeryPregnancy ComplicationsTreatment OutcomeDrug Therapy CombinationFemalebusinessmedicine.drugArthritis and rheumatism
researchProduct

Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial …

2016

Summary Background Women with a history of venous thromboembolism (VTE) have a 2% to 10% absolute risk of VTE recurrence during subsequent pregnancies. Therefore, current guidelines recommend that all pregnant women with a history of VTE receive pharmacologic thromboprophylaxis. The optimal dose of low-molecular-weight heparin (LMWH) for thromboprophylaxis is unknown. In the Highlow study (NCT 01828697; www.highlowstudy.org ), we compare a fixed low dose of LMWH with an intermediate dose of LMWH for the prevention of pregnancy-associated recurrent VTE. We present the rationale and design features of this study. Methods The Highlow study is an investigator-initiated, multicentre, internation…

Adultmedicine.medical_specialtymedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologylaw.inventionYoung Adult03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled trialRecurrencePregnancylawInternal medicineVenous thrombosisSecondary PreventionHumansMedicinecardiovascular diseasesPregnancy030219 obstetrics & reproductive medicineProphylaxisbusiness.industryPostpartum PeriodAbsolute risk reductionAnticoagulantsVenous ThromboembolismHematologyHeparinHeparin Low-Molecular-Weightmedicine.diseaseequipment and suppliesLMWHSurgeryClinical trialVenous thrombosisTreatment OutcomeGestationFemalebusinessmedicine.drug
researchProduct

High performance composites containing perfluoropolyethers-functionalized carbon-based nanoparticles: Rheological behavior and wettability

2016

Abstract Ultra High Molecular Weight Polyethylene (UHMWPE) based composites filled with carbon nanotubes (CNTs) and carbon black (CB) modified by perfluoropolyethers (PFPE) have been formulated. All composites show a segregated morphology with nanofillers selectively localized at the polymer particle–particle interface. The composites rheological properties have been deeply investigated: the PFPE functionalities linked on CNTs facilitate the semi-3D nanofillers network formation in the composites that show a solid-like behaviour even at lower investigated filler contents, reaching the rheological percolation threshold at lower nanofiller content than bare CNTs filled composites. For composi…

B. Rheological propertiePolymer-matrix composites (PMCs)Materials scienceNano-structures Polymer-matrix composites (PMCs) Rheological properties Surface properties Perfluoropolyethers nanofillersB. Surface propertiesNanoparticlechemistry.chemical_elementCeramics and Composite02 engineering and technologyCarbon nanotube010402 general chemistry01 natural sciencesPerfluoropolyethers nanofillersIndustrial and Manufacturing Engineeringlaw.inventionchemistry.chemical_compoundA. Polymer-matrix composites (PMCs)lawA. Nano-structures; A. Polymer-matrix composites (PMCs); B. Rheological properties; B. Surface properties; Perfluoropolyethers nanofillers; Ceramics and Composites; Mechanics of Materials; Mechanical Engineering; Industrial and Manufacturing EngineeringA. Nano-structuresSurface propertiesMechanics of MaterialRheological propertiesComposite materialPerfluoropolyethers nanofillerUltra-high-molecular-weight polyethylenechemistry.chemical_classificationMechanical EngineeringPercolation thresholdCarbon blackPolymer021001 nanoscience & nanotechnologyB. Surface propertie0104 chemical sciencesB. Rheological propertieschemistryNano-structuresMechanics of MaterialsA. Nano-structureCeramics and CompositesWetting0210 nano-technologyCarbon
researchProduct

Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Associated With Splenic Marginal-zone Lymphoma With Low-molecular Weig…

2008

ABSTRACT Case report A 69-year-old woman with splenic marginal-zone lymphoma was admitted with progressive abdominal pain and splenomegaly as the suspected cause of pain. Rituximab treatment (375 mg/m 2 ) had been initiated on the day of admission. Abdominal computerized tomography revealed splenic infarction. Laboratory tests showed elevation of liver enzymes and creatinine, low platelet count, prolonged partial thromboplastin time, and lupus anticoagulant positivity. The diagnosis of catastrophic antiphospholipid antibody syndrome was made. Weight-adjusted low-molecular weight heparin therapy was initiated. Freedom from symptoms and normalization of liver enzymes and creatinine occurred w…

Bendamustinemedicine.medical_specialtyLymphoma B-Cellmedicine.drug_classLow molecular weight heparinAntineoplastic AgentsGastroenterologyAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineBendamustine HydrochlorideHumansMedicineSplenic marginal zone lymphomaAgedLupus anticoagulantbusiness.industrySplenic NeoplasmsAnticoagulantAntibodies MonoclonalAnticoagulantsGeneral MedicineHeparinHeparin Low-Molecular-WeightAntiphospholipid Syndromemedicine.diseaseSurgerySplenic infarctionNitrogen Mustard CompoundsFemaleRituximabRituximabbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Wastewater treatment and reclamation : A review of pulp and paper industry practices and opportunities

2016

The pulp and paper (P&P) industry worldwide has achieved substantial progress in treating both process water and wastewater, thus limiting the discharge of pollutants to receiving waters. This review covers a variety of wastewater treatment methods, which provide P&P companies with cost-effective ways to limit the release of biological or chemical oxygen demand, toxicity, solids, color, and other indicators of pollutant load. Conventional wastewater treatment systems, often comprising primary clarification followed by activated sludge processes, have been widely implemented in the P&P industry. Higher levels of pollutant removal can be achieved by supplementary treatments, which…

Environmental EngineeringMaterials sciencelcsh:BiotechnologyACTIVATED-SLUDGE TREATMENTBioengineeringDISSOLVED-AIR FLOTATIONWastewater treatment02 engineering and technology010501 environmental sciencesWHITE-ROT FUNGI01 natural sciencesMILL EFFLUENT TREATMENTCHLORINATED ORGANIC-COMPOUNDS12. Responsible consumptionLand reclamationlcsh:TP248.13-248.65Bioreactoractivated sludgeadvanced oxidationMembrane technologiesWaste Management and DisposalEffluent0105 earth and related environmental sciencesmembrane technologiesPollutantBLEACHED KRAFT MILLpulp and paper manufacturingPulp and paper manufacturingWaste managementChemical oxygen demand021001 nanoscience & nanotechnologyPulp and paper industry6. Clean waterClarificationwastewater treatmentActivated sludgeWastewaterCATALYTIC WET OXIDATIONActivated sludge13. Climate actionANAEROBIC MEMBRANE BIOREACTORSAdvanced oxidationGREENHOUSE-GAS EMISSIONclarificationSewage treatment0210 nano-technologyMOLECULAR-WEIGHT DISTRIBUTION
researchProduct

Enhanced hybridization labeling signals in Southern blotted DNAs fractionated with voltage gradient gel electrophoresis.

1998

An enhancement of hybridization labeling signals is demonstrated in Southern blotted DNAs, fractionated by voltage gradient gel electrophoresis. This enhancement is due to a reduced thickness of each single nucleic acid band in the gel as a consequence of the gradient effect, corresponding to an increased concentration of DNA per unit area.

Gel electrophoresisElectrophoresis Agar GelChromatographyGel electrophoresis of nucleic acidsClinical BiochemistryVoltage gradientMembrane ProteinsNucleic Acid HybridizationDNAChemical FractionationBiochemistryAnalytical Chemistrychemistry.chemical_compoundBlotting SouthernchemistryMolecular-weight size markerSea UrchinsNucleic acidPulsed-field gel electrophoresisElectrochemistryAnimalsDNASouthern blotElectrophoresis
researchProduct

Use of voltage gradient gel electrophoresis in apoptotic DNA analysis

2000

In this paper the use of voltage gradient gel electrophoresis (VGGE) in the electrophoretic analysis of apoptotic DNAs is described. The peculiarity of VGGE fractionation in enhancing DNA bands in the gel by reducing their thickness was used to obtain a rapid, more selective and higher-quality electrophoretic fractionation of apoptotic DNA with respect to conventional electrophoresis. The use of VGGE fractionations also allowed a reduced amount of DNA to be used to detect a characteristic apoptotic DNA ladder pattern, in a lower agarose gel concentration, with respect to conventional electrophoretic fractionation

Gel electrophoresisInsectaChromatographyGel electrophoresis of nucleic acidsChemistryOrganic ChemistryApoptosisDNAGeneral MedicineFractionationBiochemistryAnalytical ChemistryElectrophoresischemistry.chemical_compoundElectricityMolecular-weight size markerPulsed-field gel electrophoresisAnimalsAgaroseElectrophoresis Polyacrylamide GelDNAJournal of Chromatography A
researchProduct